Compare IFRX & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFRX | FLYX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 79.8M |
| IPO Year | 2017 | N/A |
| Metric | IFRX | FLYX |
|---|---|---|
| Price | $1.14 | $3.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 765.5K | 15.4K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $73,729.00 | ★ $362,955,000.00 |
| Revenue This Year | N/A | $28.47 |
| Revenue Next Year | $1,075.42 | $22.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $0.71 | $1.90 |
| 52 Week High | $2.77 | $6.90 |
| Indicator | IFRX | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 45.26 |
| Support Level | $0.96 | $3.08 |
| Resistance Level | $1.16 | $3.46 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 88.08 | 14.39 |
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.